Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC).
Beatrice Knudsen
No relevant relationships to disclose
Noah M. Hahn
Research Funding - Bristol-Myers Squibb
Siamak Daneshmand
Research Funding - Bristol-Myers Squibb
Edwin M. Posadas
Research Funding - Bristol-Myers Squibb
Sambit Muhanty
No relevant relationships to disclose
Seth P. Lerner
Research Funding - Bristol-Myers Squibb
Guru Sonpavde
No relevant relationships to disclose